BioTech AZN

AstraZeneca Announces Approval Of Imfinzi In The US

November 26, 2025 — 02:26 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - AstraZeneca (AZN, AZN.L) said its Imfinzi, or durvalumab, in combination with standard-of-care FLOT chemotherapy has been approved in the US for the treatment of adult patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. The approved regimen includes neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.

The approval follows Priority Review by the FDA and is based on event-free survival and overall survival data from the MATTERHORN Phase III trial. The company noted that the US regulatory submission was reviewed under Project Orbis.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech
Stocks Mentioned
AZN

Latest Articles
Data is currently not available